Myriad Genetics
MYGN
188 hedge funds and large institutions have $1.88B invested in Myriad Genetics in 2023 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 65 increasing their positions, 64 reducing their positions, and 23 closing their positions.
3,704% more call options, than puts
Call options by funds: $16.5M | Put options by funds: $433K
2% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 64
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $1.91B → $1.88B (-$30.8M)
9% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 23
1% less funds holding
Funds holding: 190 → 188 (-2)
1.75% less ownership
Funds ownership: 101.27% → 99.52% (-1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
ExodusPoint Capital Management
New York
|
+$7.89M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$7.23M |
| 3 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$6.51M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$6.26M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$6.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$21.5M |
| 2 |
Millennium Management
New York
|
-$10.4M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$10.1M |
| 4 |
GCM
Glenview Capital Management
New York
|
-$9.83M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$8.13M |
MYGN Hedge Fund Activity: Q2 2023 in Review
188 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q2 2023, worth a combined $1.88B — down 1.6% from $1.91B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of MYGN and 21 opened new positions — a net loss of 2 holders — while 64 trimmed existing stakes and 65 added.
The largest buyer was ExodusPoint Capital Management, opening a new position worth an estimated $7.89M. The largest seller was Wellington Management Group, cutting an estimated $21.5M.
- 188 institutional investors held Myriad Genetics (MYGN) as of Q2 2023, down from 190 in Q1 2023.
- Funds reported $1.88B of Myriad Genetics stock for Q2 2023, down 1.6% quarter-over-quarter.
- 21 funds opened new Myriad Genetics positions in Q2 2023 and 23 closed out, a net change of -2 holders.
- The largest Myriad Genetics buyer in Q2 2023 was ExodusPoint Capital Management, an estimated $7.89M added.
- The largest Myriad Genetics seller in Q2 2023 was Wellington Management Group, an estimated $21.5M sold.
Based on aggregated 13F filings for Q2 2023.